HER2遺伝子変異陽性肺がんに対するトラスツズマブ エムタンシンの第Ⅱ相Basket試験、部分奏効率は44%で主要評価項目を達成【JCO】

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

J Clin Oncol 2018年7月10日オンライン版

Abstract

Purpose
Human epidermal growth factor receptor 2 (HER2, ERBB2)–activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*